Pegcetacoplan-¹³C₃,₁₅N TFA 

Pegcetacoplan-¹³C₃,¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).

1. This compound can be used as a tracer.
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(C₂H₄O)_nC₁₇₀H₂₄₈N₅₀O₄₇S₄·xC₂HF₃O₂

Ac-Ile-Cys-Val-Trp(Me)-Gln-Asp-Trp-Gly-Ala(13C3,15N)-His-Arg-Cys-Thr-PEG2-Lys-NH2(Cys and Cys bridge，Dimer with PEG40000)

Ac-ICV-{Trp(Me)}-QDWG-{Ala(13C3,15N)}-HRCY-PEG2-K-NH2(Cys and Cys bridge，Dimer with PEG40000)

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.